Nytricx, Inc.
Nytricx, Inc. is dedicated to combating medical device infections and thrombosis through innovative nitric oxide (NO)-releasing biomaterials. This technology aims to enhance the functional lifetime of medical devices by reducing infection and thrombotic events, leveraging the natural properties of nitric oxide.
Industries
Nr. of Employees
small (1-50)
Products
NO-releasing ultra-low fouling antibacterial surfaces for urological catheters (SBIR Phase I)
Project to develop ultra-low fouling catheter surfaces that locally release nitric oxide to reduce bacterial adhesion and infection in urological catheter applications.
Local nitric oxide release to enhance prosthetic vascular graft function (STTR Phase I)
Project aimed at improving prosthetic vascular graft performance by localized nitric oxide release to reduce thrombosis and improve graft patency.
Ultra-low fouling, anti-infective, anti-thrombotic NO-releasing intravascular catheters (STTR Phase II)
Program to develop intravascular catheters with combined ultra-low fouling properties and sustained nitric oxide release to reduce infection and thrombosis.
Nitric oxide-driven antimicrobial dressing combined with rapid blood clotting agent (CDMRP)
Development of an antimicrobial dressing that releases nitric oxide and is combined with a rapid hemostatic agent to achieve infection control and promote hemostasis in traumatic injuries.
Prevention of ECMO circuit thrombosis and infection by surface release of nitric oxide (BARDA)
Project to prevent thrombosis and microbial colonization in extracorporeal membrane oxygenation (ECMO) circuits by applying surfaces that release nitric oxide.
NO-releasing ultra-low fouling antibacterial surfaces for urological catheters (SBIR Phase I)
Project to develop ultra-low fouling catheter surfaces that locally release nitric oxide to reduce bacterial adhesion and infection in urological catheter applications.
Local nitric oxide release to enhance prosthetic vascular graft function (STTR Phase I)
Project aimed at improving prosthetic vascular graft performance by localized nitric oxide release to reduce thrombosis and improve graft patency.
Ultra-low fouling, anti-infective, anti-thrombotic NO-releasing intravascular catheters (STTR Phase II)
Program to develop intravascular catheters with combined ultra-low fouling properties and sustained nitric oxide release to reduce infection and thrombosis.
Nitric oxide-driven antimicrobial dressing combined with rapid blood clotting agent (CDMRP)
Development of an antimicrobial dressing that releases nitric oxide and is combined with a rapid hemostatic agent to achieve infection control and promote hemostasis in traumatic injuries.
Prevention of ECMO circuit thrombosis and infection by surface release of nitric oxide (BARDA)
Project to prevent thrombosis and microbial colonization in extracorporeal membrane oxygenation (ECMO) circuits by applying surfaces that release nitric oxide.
Expertise Areas
- Nitric oxide-releasing biomaterials
- Antimicrobial surface coatings
- Antithrombotic device coatings
- Preclinical testing with small animal models
Key Technologies
- Nitric oxide (NO) release/delivery
- NO-releasing polymers
- Surface coatings for anti-fouling
- Hemocompatibility testing
Key People
Hitesh Handa, PhD
Founder and Chief Scientific Officer
Ronald Shebuski, PhD
Founder and President & CEO
Elizabeth Brisbois, PhD
Founder and Chief Technical Officer
Hitesh Handa, PhD
Founder and Chief Scientific Officer
Ronald Shebuski, PhD
Founder and President & CEO
Elizabeth Brisbois, PhD
Founder and Chief Technical Officer